Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects
Abstract Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in healthy subjects to evaluate the eff...
Saved in:
Main Authors: | Chia‐Hsiang Hsueh (Author), Kacey Anderson (Author), Gong Shen (Author), Chohee Yun (Author), Ann Qin (Author), Ahmed A. Othman (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches
by: Dung Nguyen, et al.
Published: (2024) -
Divergent Regulation of OCT and MATE Drug Transporters by Cadmium Exposure
by: Hong Yang, et al.
Published: (2021) -
A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions
by: Denise Türk, et al.
Published: (2020) -
Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019) -
Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats
by: Yoo-Seong Jeong, et al.
Published: (2019)